For patients with p16-negative advanced PCs requiring definitive RT or CRT, treatment outcomes can be stratified by the immunohistochemical biomarkers of VEGF and GLUT1 and CT-based tumor volume. The gene discussed is VEGFA; the disease is neoplasm.